Brielle Urciuoli


JAK Inhibition in Myelofibrosis Treatment May Cause Aggressive Lymphoma in Small Percentage of Patients

September 03, 2018

Although JAK inhibitors are a proven effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside; in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.

Proposed Bill Would Reimburse Providers for Creating Survivorship Plans for Patients with Medicare

April 13, 2018

Two congressmen, who are also cancer survivors, proposed the Cancer Care Planning and Communications (CCPC) Act, which would create a Medicare billing code that would reimburse providers for their time and resources used to create survivorship care plans for patients with Medicare.

FDA Approves Rubraca for Ovarian Cancer Maintenance Treatment

April 06, 2018

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.